12.8 c
Monday, December 4, 2023

Medii x Pfizer launches initiative to accelerate and optimize physician referrals related to heart failure practice support!

Medii and Pfizer have teamed up to launch an initiative in March 2023 to promote close examination of causes in heart failure cases using E-Consult ®︎, an online specialist consultation service exclusively for physicians provided by Medii!

Background of Collaboration

Heart failure is a life-shortening disease that gradually worsens as the heart's function declines, causing shortness of breath and swelling. Since the incidence of heart failure increases with age, a "heart failure pandemic" is predicted in Japan, a super-aging society, where the number of patients is expected to increase dramatically.

There are various causes of heart failure, including hypertension, cardiomyopathy, myocardial infarction, valvular disease, and arrhythmia. Since there is an appropriate treatment for each causative disease, close examination of the cause is extremely important in heart failure cases. Cardiac amyloidosis, a rare, progressive, and fatal disease, is one of the most common causes of heart failure. However, the lack of characteristic symptomatic findings and the lack of experience in diagnosis and treatment of this disease make it difficult for many attending physicians to decide whether to refer patients to specialized facilities or not, and thus diagnosis and appropriate treatment often fail to be made. This often results in failure to diagnose and provide appropriate treatment.

Medii offers "E-Consult ®︎," an online specialist consultation service exclusively for physicians, to bring the knowledge and experience of a limited number of specialist physicians to medical practices in need, particularly in the areas of rare and intractable diseases.

Pfizer is committed to improving the diagnosis rate of heart failure patients, including cardiac amyloidosis, in line with its corporate objective to "create breakthroughs that make a significant difference in patients' lives. Pfizer will collaborate on Medii's efforts to share this specialist knowledge.

This collaboration was born out of Pfizer Healthcare Hub Japan, Pfizer's global initiative to collaborate with startup companies to provide better solutions for patients.

*The press releases of both companies at the start of the study can be found at the following link.
Pfizer Japan Pitch Event at the 3rd Pfizer Healthcare Hub Japan|News|Medii Inc.
■ Third Pfizer Healthcare Hub Japan Pitch Event Held to Discuss Solutions with Startups to Deliver Breakthroughs to Patients - | pfizer.co.jp Press Releases

Together, Medii and Pfizer aim to create a society where all patients have access to more specialized care.

Medii has launched a disease awareness website with information on heart failure and cardiac amyloidosis to provide physicians with the latest information on the disease. Furthermore, by utilizing "E-Consult ®︎," which allows physicians involved in heart failure treatment to consult with specialists online free of charge, the site will lead to early diagnosis and appropriate treatment of heart failure and cardiac amyloidosis. The initiative will initially be launched in the Kinki area and will be expanded nationwide. Pfizer will cooperate in this initiative by introducing "E-Consult ®︎" to specialists and general physicians.

Heart Failure/Cardiac Amyloidosis Awareness Site:https://medii.jp/HF_ATTRCMconsultant/

Medii will also hold seminars for physicians to improve the diagnosis rate of heart failure/ cardiac amyloidosis and provide case information.

What is "E-Consult®"?

E-Consult®" provided and operated by Medii is a completely free online service that allows physicians to consult with specialists outside the hospital or in distant locations. Difficult-to-diagnose or non-specialized cases can be consulted anonymously through the chat function on "E-Consult".

More than 800 specialists recommended by physicians in all specialties cooperate in the response process, and the system notifies and matches the most appropriate specialist according to the content of the consulting physician. The system handles all specialties with a focus on immunological intractable diseases and rare diseases where knowledge is not widely available due to the uneven regional distribution of knowledge.

About Pfizer

Pfizer leverages science and global resources to deliver treatments that help people live longer, healthier lives and significantly improve their lives. We strive to establish standards of quality, safety and value in the discovery, development and manufacture of healthcare products, including innovative medicines and vaccines.
Every day, Pfizer employees contribute to the health of people around the world by providing better prevention and treatment for life- and life-threatening diseases. As one of the world's leading innovative pharmaceutical companies, we are committed to working with healthcare professionals, governments, and communities around the world to ensure that everyone has easy access to reliable healthcare. We have been moving forward for more than 170 years to meet people's expectations.

name of companyPfizer Japan Inc.
EstablishmentAugust 1, 1953
LocationShinjuku Bunka Quint Building, 3-22-7 Yoyogi, Shibuya-ku, Tokyo
representativeAkihisa Harada, President and Representative Director
Business OverviewManufacture, sale, import and export of ethical pharmaceuticals
uniform resouce locatorwww.pfizer.co.jp(Japan Corporation)www.pfizer.com(Global)

About Medii

Medii is developing a business to expand the knowledge of medical specialists online, especially in rare and intractable diseases, which are a major challenge. The company name reflects the company's desire to change the structure of medical care from the inside out (Medii: Latin) from the perspective of both physicians and patients.
With the cooperation and support of many medical specialists, we currently provide three services for physicians: "E-Consultation," "Case Bank," and "E-Confirmation," and are pursuing the essence of medicine with the aim of realizing a world where all people can receive better medical care, no matter what region they live in.

name of companyMedii Corporation
EstablishmentFebruary 20, 2020
LocationTensho Office Shinjuku 3-chome 202, 5-14-12 Shinjuku, Shinjuku-ku, Tokyo
representativeRepresentative Director Doctor Hiroki Yamada
Business OverviewProviding specialist knowledge sharing services
uniform resouce locatorhttps://medii.jp
Facebook Comments
PORT Editorial Officehttps://port.creww.me/
PORT by Creww is an open innovation media for startups, entrepreneurs, entrepreneurs in recovery, and companies seeking to create new businesses on the theme of social issues, operated by Creww Co.
- Advertisment -
- Advertisment -


Ando Hazama x Cube Earth] Innovating the world's urban OS with patented technology from Japan and the U.S.

Creww Growth Case Study Interview】Ando Hazama has selected Cube Earth, a startup company offering a "smart disaster prevention system" to local governments through the "Ando Hazama New Business Co-Creation Program 2022," an accelerator program for fiscal year 2022, utilizing Cube Earth, a geographic information system platform patented in the United States and Japan. Cube Earth, a startup company that provides municipalities with a "smart disaster prevention system" using the geographic information system platform "Cube Earth" patented in the U.S. and Japan, was selected for the Ando Hazama New Business Co-Creation Program 2022. The startup is developing next-generation social infrastructure infrastructure such as disaster prevention systems, smart cities, drones, and digital twin systems as part of the DX approach to municipal crisis management. What specific initiatives are they pursuing? We interviewed Hiroyuki Horii, Deputy General Manager of the Innovation Department, Corporate Strategy Division, Ando Hazama, Shigehiko Amo, Chairman of Cube Earth, and Zenshi Takeda, President and Representative Director.

Sanki Kogyo × Startups] Become a company that continues to be chosen|New Steps in Co-Creation with Startups

Sanki Kogyo Corporation, which will celebrate its 100th anniversary in 2025, has set its sights on becoming a company that will "continue to be chosen" in accordance with its vision for 2050, and is working to strengthen its core businesses and enhance the Sanki brand. One of our new initiatives is to strengthen our core business and improve the Sankiki brand. Therefore, as one of the new initiatives, we are challenging the "SANKI Open Innovation Program 2023". We interviewed Mr. Hiroyuki Sasaki, Facility Systems Business Department, Mr. Tadashi Ishiwata, Corporate Planning Department, Corporate Planning Office, and Mr. Naoya Tokuda, Corporate Planning Department, who are challenging the accelerator program for the first time, about their frank thoughts from their respective standpoints.

Ando Hazama × Air Digital × Kuki City] Tackling the challenge of extending healthy life expectancy through digital sports!

Ando Hazama, a general construction company that promotes the creation of new businesses through open innovation, has selected Air Digital Inc. Air Digital, Inc., a company involved in the development of digital sports space and the operation of digital sports fields, was selected for the program. Subsequently, Ando Hazama, Air Digital, and Kuki City, Saitama Prefecture, signed a collaboration agreement and are now working together on "Sports 60 & Smart," one of the largest digital sports clubs in Japan, which is located in the "Ario Washinomiya" shopping mall facility in Kuki City. What specific initiatives are being undertaken? We interviewed Tsubasa Sakakibara, Manager of the Innovation Department of Ando Hazama's Corporate Strategy Division, Sobaku Maeda, Representative Director of Air Digital, and Takeshi Kanazawa, a member of the Sports Promotion Section of the Health and Sports Department of the Kuki City Office.

Startup Recruitment] Caring for Community Health|Future Aisei Pharmacy with Roots in the Community through New Business

Aisei Pharmacy has more than 400 dispensing pharmacies nationwide. As the company will soon celebrate its 40th anniversary, we are challenging the accelerator program in search of the next pillar of our business! Aiming to become a pharmacy that is needed by local residents, the company will explore the possibility of creating new businesses. In this interview, we spoke with Hiroyuki Hori, General Manager of the Business Planning Department of Aisei Pharmacy Inc. about why Aisei Pharmacy is now taking on the challenge of open innovation with startups.
Facebook Comments